Immune intervention for type 1 diabetes, 2013-2014.
作者信息
Skyler Jay S
机构信息
Division of Endocrinology, Diabetes, & Metabolism, and Diabetes Research Institute, University of Miami Miller School of Medicine , Miami, FL.
出版信息
Diabetes Technol Ther. 2015 Feb;17 Suppl 1(Suppl 1):S80-7. doi: 10.1089/dia.2015.1510.
Abstract
摘要
相似文献
1
Immune intervention for type 1 diabetes, 2013-2014.
Diabetes Technol Ther. 2015 Feb;17 Suppl 1(Suppl 1):S80-7. doi: 10.1089/dia.2015.1510.
2
DiaPep277® and immune intervention for treatment of type 1 diabetes.
Clin Immunol. 2013 Dec;149(3):307-16. doi: 10.1016/j.clim.2013.09.001. Epub 2013 Sep 11.
3
Immune intervention for type 1 diabetes mellitus.
Int J Clin Pract Suppl. 2011 Feb(170):61-70. doi: 10.1111/j.1742-1241.2010.02580.x.
4
Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study.
Diabetes. 2006 Aug;55(8):2340-6. doi: 10.2337/db05-1320.
5
Transfusion of apoptotic beta-cells induces immune tolerance to beta-cell antigens and prevents type 1 diabetes in NOD mice.
Diabetes. 2007 Aug;56(8):2116-23. doi: 10.2337/db06-0825. Epub 2007 May 11.
6
Endurance exercise alters cellular immune status and resistin concentrations in men suffering from non-insulin-dependent type 2 diabetes.
Exp Clin Endocrinol Diabetes. 2013 Aug;121(8):475-82. doi: 10.1055/s-0033-1343395. Epub 2013 Sep 11.
7
Intensive therapy for diabetes through influence on innate immune system.
Med Hypotheses. 2009 Jun;72(6):675-6. doi: 10.1016/j.mehy.2009.01.028. Epub 2009 Mar 4.
8
Does partial preservation of residual beta-cell function justify immune intervention in recent onset Type I diabetes?
Diabetologia. 2001 Oct;44(10):1349-53. doi: 10.1007/s001250100636.
9
[Immunosuppression in Type I diabetes mellitus].
Schweiz Rundsch Med Prax. 1990 Oct 9;79(41):1225-7.
10
Biomarkers for immune intervention trials in type 1 diabetes.
Clin Immunol. 2013 Dec;149(3):286-96. doi: 10.1016/j.clim.2013.02.009. Epub 2013 Feb 27.
引用本文的文献
1
Loss of intra-islet heparan sulfate is a highly sensitive marker of type 1 diabetes progression in humans.
PLoS One. 2018 Feb 7;13(2):e0191360. doi: 10.1371/journal.pone.0191360. eCollection 2018.
本文引用的文献
1
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.
Diabetes. 2012 Sep;61(9):2340-8. doi: 10.2337/db12-0049. Epub 2012 Jun 20.
2
Dietary intervention in infancy and later signs of beta-cell autoimmunity.
N Engl J Med. 2010 Nov 11;363(20):1900-8. doi: 10.1056/NEJMoa1004809.
3
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.
Diabetologia. 2010 Apr;53(4):614-23. doi: 10.1007/s00125-009-1644-9. Epub 2010 Jan 14.
4
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.
Blood. 2010 Feb 11;115(6):1145-55. doi: 10.1182/blood-2009-02-204875. Epub 2009 Dec 9.
5
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
N Engl J Med. 2005 Jun 23;352(25):2598-608. doi: 10.1056/NEJMoa043980.
Zotero 插件